Recent Reports


2010-01-25: Medical Research, Diagnostic Substances, Life Science Tools Report
7 leading Analysts; and top management from 2 Sector Firms examine this vital industry in this 35 page report from The Wall Street Transcript.
More Information
Order this Report

2009-12-07: Consumer Health Services Report
7 leading Analysts; and top management from 2 Sector Firm examine this vital industry in this 53 page report from The Wall Street Transcript.
More Information
Order this Report

2009-11-02: Pharmaceuticals Report
3 leading Analysts; and top management from 16 Sector Firms examine this vital industry in this 76 page report from The Wall Street Transcript.
More Information
Order this Report

2009-10-19: Biotechnology Report
3 leading Analysts; 2 Money Managers; and top management from 12 Sector Firms examine this vital industry in this 70 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Real Estate: Healthcare REITs, Long-Term Care Facilities & Hospitals Report
3 analysts and 6 sector firms examine the medical real estate segment in this 45 page report from The Wall Street Transcript.
More Information
Order this Report

09.21.09: Medical Devices Report
4 analysts and 7 sector firms examine the medical devices segment in this 41 page report from The Wall Street Transcript.
More Information
Order this Report

09.14.09: Medical Research Services Report
2 analysts, and 4 sector firms examine the medical research services segment in this 23 page report from The Wall Street Transcript.
More Information
Order this Report

Search TWST Online

TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Company Interview Excerpt
ROLF STAHEL - SHIRE PHARMACEUTICALS GROUP PLC (SHPGY)


Full article published: 10/12/2001


For Subscribers

Get this article online now!

Order just this article
TWST: Can we start out with a brief overview of Shire?
Mr. Stahel: Shire has a seven-year fast-growth history. In 1993 the company was privately owned and had a value of approximately 30 million; today we are at 7.5 billion. Over the last six years we've implemented six mergers, and Shire now has about 1,600 employees with a sales-per-employee ratio of approximately 500,000, nearly twice the ratio on average for S&P 500 companies. In regards to percent EPS growth for the year 2000, Shire was in the number-one position for the pharmaceutical industry globally. Shire has a very focused strategy and has operating companies in seven out of the eight key pharmaceutical markets in the world, and it has R&D operations in the UK, the US and in Canada.

TWST: What changes do you expect in the marketplace?
Mr. Stahel: I believe marketing density is a subject that will change in the industry, both in the GP sector and in the specialist doctor sector. And that competition for in-licensing late-phase projects and products will increase over the next two or three years

 

Tickers included in this excerpt: SHPGY

 

For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.